A Study to Learn How Safe BAY2395840 is and How Well it Works in Participants Who Have Diabetic Nerve Pain

Diabetes Mellitus Clinical Trial

Official title:

A Randomized, Double-blind, Cross-over, Placebo-controlled, Multi-center, Phase 2a Study to Assess the Safety and Signal in Efficacy of BAY 2395840 in Patients With Diabetic Neuropathic Pain

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05219812
• Other study ID #: 19636
• Secondary ID: 2021-001392-17
• Status: Completed
• Phase: Phase 2
• Start date: February 16, 2022
• Est. completion date: November 21, 2022

Study information

• Verified date: November 2023
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Researchers are looking for a better way to treat people who have diabetic neuropathic pain (DNP), a condition in which diabetes results in pain due to nerve damage. People with diabetes have high blood sugar levels. Over the time, high blood sugar levels can cause damage to the nerves in the body, which results in DNP. The nerve damage in this condition is localized in a stocking and glove like pattern and starts in the feet and can move upwards on your legs. Some patients also progress having pain in their fingers/hands. People with DNP have pain in these areas as well as reduction/loss of feeling, and at times light touch can feel like pain. In this study, the researchers want to learn more about a new study treatment called BAY 2395840. BAY 2395840 works by blocking a receptor called the bradykinin B1 receptor, or B1R. This receptor is has been shown to play a role in pain perception. The researchers also want to learn how well BAY 2395840 helps to reduce pain in the study participants. To answer this question, the researchers will measure how the participants' pain changes after taking BAY 2395840 compared to a placebo. A placebo looks like a treatment but does not have any medicine in it. The researchers also want to learn how safe BAY 2395840 is for the participants to take. The study will include adults. This will be a "crossover" study. In a crossover study, all the participants will receive both treatments (BAY 2395840 and placebo), but in a different order. All participants in this study will take BAY 2395840 and a placebo as tablets by mouth. There will be 2 periods in the study. Participants taking BAY 2395840 during period 1 will switch to placebo during period 2 and vice versa. There will some time for the switch from one period to another to make sure that whatever tablet you received in period 1 is gone from your system before period 2 starts to allow for the best possible evaluation of each tablet without any confusing effects. The study is double blinded meaning that neither you nor your doctor will know which drug you are on. The sequence of double-blind placebo and BAY treatment will be determined randomly by a computerized system. During the study, the participants will visit their study site 13 times. Each participant will be in the study for about 16 weeks. The treatment duration will be about 11 weeks. During the study, the study team will: - take blood and urine samples - do physical examinations - check the participants' overall health - check the participants' heart health using an electrocardiogram (ECG) - ask the participants about any medications they have been taking, and what adverse events they are having An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: November 21, 2022
• Est. primary completion date: November 7, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adults = 18 years of age at the time of signing the informed consent.
• Have documented diagnosis of type 1 OR type 2 diabetes mellitus (DM).
• Have painful distal symmetrical sensorimotor diabetic neuropathy for at least 6 months prior to the screening and confirmed at screening via the modified Toronto Clinical Neuropathy Score with a score of at least 3.
• Weekly mean 24-hour average pain Numeric Rating Scale (NRS) = 4 with adequate variability (not the same score on all daily pain ratings) and compliance (non-missing pain score on at least 6 out of 7 consecutive days) in daily pain recording during the 7-day NRS baseline period.
• Neuropathic pain according to the Douleur Neuropathique 4 Questions (DN4 questionnaire) at screening visit with a score of at least 4 out of 10.
• Participant should be on stable antidiabetic treatment for at least 3 months prior to the screening visit and there should be no pre-planned changes to antidiabetic treatment during this study.
• Participant is willing to use only rescue medication provided by the site and is willing to withdraw temporarily all other neuropathic pain medications which were in use before study participation.
• Participant is willing and able to use the electronic hand-held device on their own.
• Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion Criteria:

• Clinically significant cardiovascular or cerebrovascular disease including Acute coronary syndrome (ACS)/myocardial infarction /stroke/Transient ischemic attack (TIA) within previous 3 months before screening visit.
• Major depressive episode within 6 months prior to screening. Patients with stable depression and on stable antidepressant dose (no change in medication and /or dosing regimen) for the past 6 months are allowed to participate, provided the antidepressant used is not listed under prohibited medications.
• Any differential diagnosis of peripheral diabetic neuropathy (PDN) including but not limited to other neuropathies (e.g. vitamin B12 deficiency, Chronic Inflammatory Demyelinating Polyneuropathy), polyradiculopathies, central disorders (e.g. demyelinating disease), or rheumatological disease (e.g. foot arthritis, plantar fasciitis).
• Concurrent malignancy or history of cancer (exception of basal cell or squamous cell carcinoma of the skin) within the last 5 years prior to screening.
• Any other diseases or conditions that according to the investigator can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study intervention (e.g. chronic bowel disease, Crohn's disease, and ulcerative colitis).
• Any serious or unstable diseases or conditions including psychiatric disorders that might interfere with the conduct of the study or the interpretation of the results.
• Major surgery or radiological procedures (e.g. Percutaneous transluminal angioplasty (PTA) and stenting of peripheral vascular lesions in lower extremities) within 3 months before screening visit or scheduled during the study period, which might interfere pain response evaluation.
• Symptomatic peripheral arterial disease in lower or upper extremities, including diabetic ulcers.
• Use of live, attenuated, replication-competent vaccines.
• Previous use of strong opioids (e.g. oxymorphone, oxycodone) for neuropathic pain anytime, or topical use of capsaicin within 3 months prior to the screening visit.
• History or current diagnosis of electrocardiogram (ECG) abnormalities indicating significant risk of safety for study participants.
• Moderate-to-severe hepatic impairment defined as Child-Pugh Class B or C.
• Have platelets = 100 x 109/L, or neutrophil count < 1.2 x 109/L (or equivalent), hemoglobin = 100 g/L for women or hemoglobin = 110 g/L for men at screening.
• Glycemic control unstable (hemoglobin HbA1c =11% or 97 mmol/mol) within 3 months prior to screening (e.g. ketoacidosis requiring hospitalization, any recent episode of hypoglycemia requiring assistance through medical intervention, uncontrolled hyperglycemia).
• ALT >2xULN, or AST >2xULN, or total bilirubin greater than ULN, or alkaline phosphatase (AP) >2x ULN, or INR greater than ULN (unless related to anticoagulation treatment) at screening.
• Positive hepatitis B virus surface antigen (HBsAg) or positive hepatitis C virus antibodies (anti-HCV) and detection of mRNA (HCV-mRNA tested only if hepatitis C virus antibodies detected).
• Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m^2 calculated by Modification of Diet in Renal Disease (MDRD) formula.
• Uncontrolled hypertension despite optimal treatment with antihypertensive(s), indicated by a sitting systolic blood pressure = 180 mmHg and/or diastolic blood pressure = 110 mmHg.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Neuralgia
• Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
• Peripheral Nervous System Diseases
• Peripheral Neuropathic Pain

Intervention

Drug:
• BAY2395840
Tablet, intake orally.
• Placebo for BAY2395840
Tablet, intake orally.

Locations

Country	Name	City	State
Czechia	NEUROHK s.r.o	Chocen
Czechia	Interni a diabetologicka ambulance - Krnov	Krnov
Czechia	Fakultni nemocnice Ostrava	Ostrava
Czechia	Vseobecna fakultni nemocnice v Praze	Praha 2
Czechia	Praglandia	Praha 5
Czechia	Vestra Clinics s.r.o.	Rychnov nad Kneznou
Czechia	Diabetologicka ambulance Vlasim	Vlasim
Germany	Herz- und Diabeteszentrum Nordrhein-Westfalen (HDZ NRW)	Bad Oeynhausen	Nordrhein-Westfalen
Germany	Klinische Forschung Berlin GbR	Berlin
Germany	InnoDiab Forschung GmbH	Essen	Nordrhein-Westfalen
Germany	Klinische Forschung Hannover-Mitte GmbH	Hannover	Niedersachsen
Germany	Klinische Forschung Karlsruhe GmbH	Karlsruhe	Baden-Württemberg
Germany	Klinische Forschung Schwerin GmbH	Schwerin	Mecklenburg-Vorpommern
Hungary	DRC Gyogyszervizsgalo Kozpont Kft.	Balatonfured
Hungary	Clinexpert Kft.	Budapest
Hungary	Coromed Smo Kft	Pecs
Slovakia	ALIAN s.r.o.	Bardejov
Slovakia	NEUROPOINT sro, Neurologicka ambulancia	Bratislava
Slovakia	Internal and Diabetes Clinic - IN-DIA s.r.o. | Lucenec, Slovakia	Lucenec
Slovakia	Vseobecna nemocnica v Ziari nad Hronom	Ziar nad Hronom
Slovakia	Medivasa s.r.o.	Zilina
Slovakia	Neuron - D.T. sro, Neurologicka ambulancia	Zilina
Spain	Gerencia de Gestion Integrada A Coruna | Department of Endocrinology and Nutrition	A Coruna	A Coruña
Spain	Hospital General Universitario de Alicante	Alicante
Spain	Complexo HU Ferrol | Endocrinología y Nutrición	Ferrol	A Coruña
Spain	Hospital Univ. Bellvitge | Anestesiología y Unidad del Dolor	L'Hospitalet de Llobregat	Barcelona
Spain	Hospital Gregorio Maranon | Endocrinology Department	Madrid
United Kingdom	King's College Hospital - NHS Foundation Trust	London
United Kingdom	MAC Research Centre - Manchester	Manchester
United Kingdom	MAC Clinical Research - Teesside	Teesside	Stockton-on-Tees

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Countries where clinical trial is conducted

Czechia,  Germany,  Hungary,  Slovakia,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in weekly mean 24-hour average pain intensity score using the 11-point Numeric Rating Scale (NRS) from baseline to the end of intervention	NRS is an one-item assessment of average neuropathic pain intensity which is presented as an 11-point Likert scale with 0 as "no pain" and 10 as "worst imaginable pain".	Baseline to end of intervention (in total up to 16 weeks)
Secondary	Change in Neuropathic Pain Symptom Inventory (NPSI) score from baseline to the end of intervention.	The Neuropathic Pain Symptom Inventory (NPSI) is a PRO developed to evaluate different symptoms of neuropathic pain.	At visit 2, visit 4, visit 6, visit 8, visit 10 and at visit 12 end of intervention (EOI).
Secondary	Change in Patient Global Impression of Severity (PGI-S) score from baseline to the end of intervention.	The PGI-S is a one-item self-reported instrument used to assess to assess patients' impression of disease severity with a 6-point scale response options, scores ranging from 1 ("none") to 6 ("very severe).	At visit 2, visit 4, visit 6, visit 8, visit 10 and at visit 12 end of intervention (EOI).
Secondary	The proportion of participants achieving a =30% and a =50% reduction in weekly mean 24-hour average pain intensity score (i.e. responder rates using NRS)		From baseline to end of intervention (in total up to 12 weeks)
Secondary	Number of participants with treatment emergent adverse events (TEAE)		From start of study intervention to 14 days after last dose.

External Links

•   Click here to find further information and, after study completion, the study results according to Bayer's transparency standards
•   Click here to find information about studies related to Bayer Healthcare products conducted in Europe